Cochrane · systematic review · CD004524
Methotrexate for ankylosing spondylitis
Chen, J, Veras, MMS, Liu, C, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
2
No studies
5
Included studies
NR
No studies 5 · 71.4%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
MTX treated compared to no MTX treated for AS
Population: Patients with AS
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
ASAS 40 MTX treated vs no MTX treated | no estimate extracted | NR | No studies |
Partial remission MTX treated vs no MTX treated | no estimate extracted | NR | No studies |
BASFI (score from 0 to 10, 0=excellent, 10=poor function) MTX treated vs no MTX treated | no estimate extracted | 1 study · 35 participants | Low |
X‐Ray of the spine MTX treated vs no MTX treated | no estimate extracted | NR | No studies |
MRI MTX treated vs no MTX treated | no estimate extracted | NR | No studies |
Serious adverse event MTX treated vs no MTX treated | no estimate extracted | NR | No studies |
Withdrawal for any reason MTX treated vs no MTX treated | RR 1.06 [0.07, 15.62] | 1 study · 35 participants | Low |